Список проголосовавших за комментарий " Gapping up/down: DATA +15%, FTNT +13%, V +4%, CLX +3% and HMC +3% after earnings, banking stocks trading higher after reports of Dodd-Frank review; DECK -21%, FEYE -18%, GPRO -14% after eanings<p><strong>Gapping up<br/> In reaction to strong earnings/guidance</strong>:</p><ul><li><strong>PXLW</strong> +19.4%, <strong>DATA</strong> +15.1%, <strong>FTNT</strong> +13%, <strong>PCTY</strong> +8.5%, <strong>BPY</strong> +7.7%, <strong>PFSI</strong> +5.6%, <strong>AVIR</strong> +5%, <strong>ESL</strong> +4.6%, <strong>IXYS</strong> +4.2%, <strong>V</strong> +3.9%, <strong>CY</strong> +3.6%, <strong>CLX</strong> +2.9%</li><li><strong>HMC</strong> +2.9%, <strong>CENT</strong> +2.7%, <strong>AMGN</strong> +2.5%, <strong>AIV</strong> +1.7%, <strong>ESS</strong> +1.6%, <strong>XPLR</strong> +1.2%, <strong>THG</strong> +1.2%</li></ul><p><strong>M&A news</strong>:</p><ul><li><strong>CERU</strong> +13.9% (likely on continued M&A sepculation (strategic alternatives announced Feb 1))</li></ul><p><strong>Select financial names showing strength amid headlines that President Trump will begin acting today on plans to reduce regulatory burdens on the financial sector, with the review Dodd-Frank and reversal of the Fiduciary Rule</strong>:</p><ul><li><strong>BCS</strong> +2.5%, <strong>BAC</strong> +1.7%, <strong>GS</strong> +1.6%, <strong>C</strong> +1.4%, <strong>CS</strong> +0.7%, <strong>ING</strong> +0.7%</li></ul><p><strong>Other news</strong>:</p><ul><li><strong>MDCO</strong> +10.5% (following Amgen's Repatha update and earnings)</li><li><strong>IPCI</strong> +10.4% (announces FDA acceptance for filing of NDA for Rexista (oxycodone hydrochloride extended release), an abuse deterrent opioid analgesic for the treatment of moderate to severe pain)</li><li><strong>ESPR</strong> +10% (following Amgen's Repatha update and earnings)</li><li><strong>SDRL</strong> +6.1% (modestly rebounding following recent weakness)</li><li><strong>AMGN</strong> +2.5% (announces Repatha significantly Reduced the risk of cardiovascular events in FOURIER Outcomes Study — Landmark Repatha Cardiovascular Outcomes Study meets primary and key secondary endpoint)</li><li><strong>PANW</strong> +1.7% (in sympathy with FTNT earnings</li><li><strong>MA</strong> +1.3% (in sympathy with V earnings)</li><li><strong>REGN</strong> +1% (following Amgen's Repatha update and earnings)</li></ul><p><strong>Analyst comments</strong>:</p><ul><li><strong>RIG</strong> +1.3% (upgraded to Outperform from Neutral at Credit Suisse )</li><li><strong>AMTD</strong> +1.3% (upgraded to Outperform from Neutral at Credit Suisse)</li><li><strong>F</strong> +0.9% (upgraded to Overweight from Equal Weight at Barclays )</li><li><strong>FCAU</strong> +0.7% (upgraded to Equal Weight at Barclays)</li></ul><p><strong>Gapping down<br/> In reaction to disappointing earnings/guidance</strong>:</p><ul><li><strong><strong>DECK</strong></strong> -20.7%, <strong>FEYE</strong> -18.3%, <strong>GIMO</strong> -14.3%, <strong>GPRO</strong> -13.7%, <strong>HBI</strong> -9.7%, <strong>ELY</strong> -8.9%, <strong>ATHN</strong> -8%, <strong>ACET</strong> -5.2%, <strong>AMZN</strong> -4.3%</li><li><strong>MWA</strong> -3.9%, (Increases diviend 33%, Announces up to $250 mln share repurchase (Included prior repurchase); Names <strong>J</strong>. Scott Hall CEO)</li><li><strong>GFI</strong> -2.8%, <strong>PMT</strong> -2.5%, <strong>VR</strong> -1.9%, <strong>HIG</strong> -1.7%, <strong>AN</strong> -1.7%, <strong>RTEC</strong> -1.5%, <strong>WY</strong> -1.4%, <strong>BRS</strong> -0.9%, <strong>PSX</strong> -0.7%, <strong>WETF</strong> -0.5%</li></ul><p><strong><strong>Select metals/mining stocks trading lower</strong>:</strong></p><ul><li><strong><strong><strong>VALE</strong></strong></strong> -4%, <strong>RIO</strong> -3.6%, <strong>BBL</strong> -3.4%, <strong>BHP</strong> -3%, <strong>CLF</strong> -2.2%, <strong>X</strong> -1.8%, <strong>MT</strong> -1.7%, <strong>FCX</strong> -1.5%, <strong>AKS</strong> -1.5%, AG -1.4%, <strong>SLW</strong> -1.4%, <strong>GOLD</strong> -1.2%, <strong>PAAS</strong> -1%, <strong>ABX</strong> -1%</li></ul><p><strong><strong>Other news</strong>:</strong></p><ul><li><strong><strong>IDXG</strong></strong> -21.3% (commences common stock offering)</li><li><strong>XGTI</strong> -12.7% (intends to offer for sale shares of its common stock and warrants to purchase its common stock in an underwritten public offering; size not disclosed), <strong>NEOS</strong> -10.3% (provides corporate update in conjunction with today's common stock offering; co sees Q4 revs just short of estimates; commences common stock offering; size not disclosed)</li><li><strong>RUBI</strong> -6.3% (indicated lower following block trade pricing)</li><li><strong>SBGL</strong> -4.2% (reports H1 gold production in-line with LY; also expressed its intention to raise a between a minimum of $750 mln and $1 bln dollars in the equity capital markets)</li><li><strong>H</strong><strong>TBX</strong> -4.1% (files prospectus supplement pursuant to which it may sell shares of its common stock having an aggregate offering price of up to $17.5 mln)</li><li><strong>AMBA</strong> -2.6% (following GPRO earnings)</li><li><strong>VOD</strong> -1% (continued weakness following yday's earnings)</li></ul><p><strong><strong>Analyst comments</strong>:</strong></p><ul><li><strong><strong>CLVS</strong></strong> -6.1% (downgraded to Sell at Chardan Capital Markets)</li><li><strong>ARRY</strong> -2% (downgraded to Neutral from Overweight at JP Morgan)</li><li><strong>LULU</strong> -1.5% (downgraded to Sector Weight from Overweight at KeyBanc Capital Mkts)</li><li><strong>RL</strong> -1% (downgraded to Neutral from Buy at UBS)</li><li><strong>PRXL</strong> -0.8% (downgraded to Neutral from Buy at Citigroup; downgraded to Sell from Hold at Deutsche Bank)</li></ul>"